Upon successful completion of the program, participants should be better able to: 

• Assess  differences and best uses for  continuous glucose monitors (CGMs), insulin pumps, and integrated devices.
• Discuss appropriate settings for CGMs, connected pens, insulin pumps, and integrated devices.
• Identify interventions which can add value to A1c interpretation and optimize “in-target” glucose values to improve patient adherence and reduce the occurrent of dysglycemia.
• Incorporate diabetes technologies that are effective in managing patients in special populations and individual needs.
• Navigate insurance challenges when implementing diabetes technologies.

Disclosure Policy

In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.

Faculty

Matthew Levine, MD, FACE, Novo Nordisk, speakers' bureau on diabetes; Eli Lilly, speakers' bureau on diabetes; Mannkind, consultant

Jeff Unger, MD, FAAFP, FACE, Abott Diabetes, consultant and speakers' bureau; Dexcom, consultant

Claire Ingram, PA-C, no relationships to disclose

Lucy Thornton, MSN, APRN, FNP-BC, no relationships to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.

Planners

Amy Ogunsunlade, no relationships to disclose

Diane Alberson, MEd, CAE​, no relationships to disclose

Contributer/Reviewer

Carla Cox, PhD, RDN, FADCES, Certified Diabetes Care and Education Specialist (CDCES), Certified Insulin Pump and CGM Trainer Mountain Vista Medicine, South Jordan, UT American Diabetes Association, Arlington, VA

Carla Cox, PhD, RDN, FADCES has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

• Matthew J. Levine, MD, FACE​ - Clinical Endocrinologist, ​Endocrinology Fellowship Director​Scripps Clinic, La Jolla CA, ​Assistant Clinical Professor of Medicine, U.C. San Diego School of Medicine
• Jeffrey R. Unger, MD FAAFP, FACE - Director, Unger Primary Care Concierge Medical Group
• Lucy H. Thornton, MSN, APRN, FNP-BC​ - Division of Endocrinology​, Mayo Clinic Florida
• Claire Ingram, PA-C - Physician Assistant​, University of Colorado Anschutz Medical Campus​